New Flowserve digital positioner features predictive diagnostics
Flowserve Corporation, a leading provider of flow control products and services for the global infrastructure markets, has announced the release of the Flowserve Logix 3400MD, the newest member of the Logix series digital positioner family
'Next-generation facilities use Foundation Fieldbus technology because it allows easy integration of field instruments into a central control system,' said Ken Beatty, Director of Advanced Product Development, Flowserve Flow Control Division. 'The Logix 3400MD helps plant operators run their control processes more efficiently by identifying issues before they become costly failures.'
The Logix 3400MD uses Flowserve ValveSight technology to monitor the status of the valve, actuator and positioner, and the health of the entire control loop. Proprietary models provide predictive diagnostics, which give advanced warning of future equipment or process problems.
The Flowserve Logix 3400MD features the same proven, state-of-the-art technology as the Logix 3200MD to provide superior performance and reliability. It is certified by all major digital control system suppliers, the FDT Group and the Fieldbus Foundation.
For more information about the Logix 3400MD digital positioner, please call a Flowserve sales representative at +1 800 225-6989.
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months